logo
Plus   Neg
Share
Email

Stars Group To Acquire Remaining 20% Of BetEasy - Quick Facts

The Stars Group Inc. (TSG, TSGI.TO) announced Monday that it has agreed with the minority shareholders of BetEasy, its Australian-based sports betting business, to acquire the remaining 20 percent interest in the company for A$151 million.

As part of this agreement, The Stars Group also agreed to pay A$100 million to settle the previously disclosed performance payment under the agreements for its 2018 acquisition of the initial 80 percent interest.

The Stars Group currently expects to complete the minority acquisition within 90 days following the earlier of either the issuance of The Stars Group's audited financial statements for the year-ended December 31, 2020 or the completion of the previously announced board-recommended all share combination of The Stars Group with Flutter Entertainment Plc.

The purchase price will be settled in cash unless it follows the completion of the combination, in which case Flutter may elect to settle in cash, Flutter ordinary shares or a combination of the same.

In addition to the acquisition of the remaining interest, The Stars Group will settle the performance, or earn-out, payment to the minority shareholders for A$100 million. The performance payment, which could have reached A$232 million, was subject to certain performance conditions primarily related to BetEasy's EBITDA.

Also as part of the agreement, The Stars Group will repay A$56.9 million of outstanding BetEasy minority shareholder loans.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL.
Follow RTT